secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autolus Therapeutics plc (AUTL)
CIK:        0001730463
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0001730463-24-000045
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 4.02
LLM model:  deepseek-v4-flash:cloud@v2

Autolus restates 2021-2022 financials on R&D tax credit classification error
----------------------------------------------------------------------------

- Error: UK SME R&D tax credits previously classified as income tax benefit should reduce R&D expense instead.
- Audit committee concluded non-reliance on FY2021 and FY2022 annual and interim financial statements on March 15, 2024.
- Restatement reduces income tax benefit by $24.6M (2022) and $24.0M (2021), with offsetting cuts to R&D expense; net loss unchanged.
- Company will correct error in upcoming 10-K for FY2023; no prior filings will be amended.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000045/0001730463-24-000045-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1730463/000173046324000045/autl-20240321.htm
  HTML page:      https://secwatch.observer/filing/0001730463-24-000045

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer